Lab publishes work using metabolic remodeling to improve immunotherapy

Immunotherapy is likely hampered by a metabolically restrictive tumor microenvironment. This week in Cancer Immunology Research, our paper went live describing a role for the type II diabetes drug metformin as a metabolic remodeling agent that enables effective immunotherapy in mouse models!